📚 Part of the TILA-278 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Program Risk Register (TILA-278)

Field	Value
Document ID	PM-004
Version	1.0
Compound	TILA-278 (anti-TL1A antagonist / IL-22R agonist bispecific)
Standard	program management
Confidentiality	Confidential

Program-management document for the TILA-278 development program.

Change History

Version	Date	Author	Summary
1.0	2026-07-08	Program Management	Initial issue

1. Purpose and Scope

This section presents the integrated Program Risk Register for TILA-278 (Virtual Biopharma Inc.), a humanized IgG1 bispecific monoclonal antibody combining anti-TL1A (TNFSF15) antagonism with IL-22 receptor agonism, administered subcutaneously (SC) for the treatment of moderate-to-severe ulcerative colitis (UC). The register consolidates the principal clinical, safety, regulatory, chemistry-manufacturing-and-controls (CMC), nonclinical, and operational risks to program success, with an assessment of likelihood and impact, defined mitigations, residual risk, and accountable owners.

The register is a living program-management instrument maintained by the Program Management Office (PMO) and endorsed by the cross-functional Program Team. It is aligned with the quality risk management principles of ICH Q9(R1) and with the risk-based quality-management expectations of ICH E6(R3), and it cross-references the substantive assessments held in the technical modules of this dossier (Module 2.4 Nonclinical Overview, Module 2.5 Clinical Overview, Module 2.6/2.7 Summaries, Module 3.2.S/3.2.P for drug substance and drug product, and Module 5 clinical study reports). It reflects program status as of the current Phase 2b induction data readout from Study TILA278-201 and is intended to support End-of-Phase-2 planning and the transition to a confirmatory program.

The register covers risks material to the approvability, timeline, cost, and commercial viability of the TILA-278 development program. It does not restate the full benefit-risk assessment, which is provided in Module 2.5; rather, it identifies where residual uncertainty warrants active management, monitoring, and escalation.

2. Risk Assessment Methodology

Each risk has been scored on a five-point likelihood scale and a five-point program-impact scale. The inherent risk score (pre-mitigation) and the residual risk score (post-mitigation) are the product of the likelihood and impact ratings (range 1–25) and are banded as Low, Medium, or High. Scoring is qualitative and consensus-based across the responsible functions; it is reassessed at each scheduled program review (Section 6).

Table 2-1. Likelihood scale

Score	Rating	Definition (probability within the program planning horizon)
1	Rare	< 10%
2	Unlikely	10–30%
3	Possible	30–50%
4	Likely	50–75%
5	Almost certain	> 75%

Table 2-2. Program-impact scale

Score	Rating	Definition
1	Negligible	No material effect on timeline, cost, or approvability
2	Minor	Minor timeline/cost effect; no approvability or label impact
3	Moderate	Measurable delay (≤ 3 months) or additional analyses/studies; manageable
4	Major	Significant delay (3–9 months), substantial cost, and/or potential label restriction
5	Critical	Program-threatening: non-approval, clinical hold, or delay > 9 months

Table 2-3. Risk banding (Likelihood × Impact)

Band	Score range	Management expectation
Low	1–5	Monitor; manage within functional plans
Medium	6–11	Active mitigation with owner accountability; tracked at program review
High	12–25	Priority mitigation; governance oversight and defined escalation triggers

3. Risk Governance and Ownership

Accountable owners are the functional leaders empowered to direct mitigation and to escalate. The PMO maintains the register, drives the review cadence, and reports the aggregate risk profile to the Program Team and to the Development Governance Committee. Given the Sponsor's largely outsourced operating model, alliance and vendor-oversight accountabilities are explicitly assigned.

Table 3-1. Owner role key

Abbreviation	Accountable owner
CMO	Chief Medical Officer
HCD	Head of Clinical Development
HCO	Head of Clinical Operations
HCP	Head of Clinical Pharmacology
HPV	Head of Pharmacovigilance / Drug Safety
HBS	Head of Biostatistics
VPRA	VP Regulatory Affairs
VPCMC	VP CMC / Technical Operations
HNC	Head of Nonclinical Safety
HQA	Head of Quality Assurance
CPL	Combination-Product / Device Lead
PMO	Program Director (PMO)
CBO	Chief Business Officer / Alliance Management
CEO	Chief Executive Officer

4. Program Risk Register

Risks are grouped by domain. For each, the register records inherent and residual bands; the primary mitigations are summarized here and expanded for priority risks in Section 5.

4.1 Clinical and Safety Risks

Table 4-1. Clinical and safety risk register

ID	Risk	L	I	Inherent	Residual	Owner	Primary mitigations
RR-CL-01	Immunogenicity (ADA) attenuating exposure/efficacy or altering safety, elevated by the bispecific format and SC route	4	4	High (16)	Medium (6)	HCP	Validated tiered ADA assay (screen/confirm/titre/neutralizing) with PK-, efficacy-, and safety-impact analyses; humanized, low-immunogenicity-engineered construct; ADA-covariate population-PK modelling to inform Phase 3 dose/interval
RR-CL-02	IL-22R agonism promoting aberrant epithelial proliferation / colitis-associated neoplasia	2	5	Medium (10)	Medium (8)	HNC/CMO	Chronic NHP toxicology with detailed GI histopathology and proliferation markers; long-term pharmacovigilance plan with malignancy surveillance; exposure caps informed by no-observed-adverse-effect level
RR-CL-03	Increased infection risk from combined immunomodulation (TL1A antagonism dampening TH1/TH17)	3	3	Medium (9)	Medium (6)	HPV	Protocol exclusion of active/latent infection (incl. TB screening); prospective infection AE adjudication; routine PV signal detection. In TILA278-201 no dose-dependent safety signal was observed and serious infections were not increased over placebo
RR-CL-04	Durability of benefit beyond induction unestablished; only 12-week induction data available (remission Week 12: High 37.3%, Low 16.2%, Placebo 0.7%)	4	4	High (16)	Medium (6)	HCD	Confirmatory induction-plus-maintenance design (treat-through and/or randomized withdrawal); long-term extension for durability and loss-of-response characterization
RR-CL-05	Injection-site reactions affecting adherence and potentially blinding	4	2	Medium (8)	Low (3)	HCD	ISR were the main drug-attributable finding and were non-serious; formulation/device optimization; standardized injection technique and ISR management guidance
RR-CL-06	Anomalously low placebo remission (0.7%) inviting scrutiny of endpoint/assay conduct	3	3	Medium (9)	Low (4)	HBS	Central endoscopy reading with blinded adjudication; sensitivity analyses; documented modified-Mayo scoring conventions; reconfirmed in the confirmatory program with prospective central reading

4.2 Regulatory Risks

Table 4-2. Regulatory risk register

ID	Risk	L	I	Inherent	Residual	Owner	Primary mitigations
RR-RA-01	Novel IL-22R-agonist mechanism with no approved precedent; heightened agency caution on benefit-risk and long-term safety	4	4	High (16)	Medium (9)	VPRA	Early and iterative health-authority engagement (scientific advice / End-of-Phase-2 and equivalent regional meetings); robust ICH S6(R1)-based nonclinical justification; agreed long-term safety and risk-management plan
RR-RA-02	Non-alignment on confirmatory design (endpoints, co-primary induction/maintenance, statistical plan)	3	4	High (12)	Medium (6)	VPRA	Special Protocol Assessment / equivalent; pre-agreed estimands aligned to current UC guidance; harmonized primary endpoint (clinical remission, modified Mayo ≤ 2, no subscore > 1)
RR-RA-03	Divergent US/EU/other-region expectations delaying multi-regional filing	3	3	Medium (9)	Low (4)	VPRA	Parallel scientific advice; single multi-regional confirmatory program; region-specific bridging pre-agreed
RR-RA-04	Combination-product (prefilled syringe/autoinjector) regulatory pathway complexity	3	3	Medium (9)	Low (4)	VPRA/CPL	Early device constituent-part strategy; design-control and human-factors dossier aligned to device-specific requirements

4.3 CMC Risks

Table 4-3. CMC risk register

ID	Risk	L	I	Inherent	Residual	Owner	Primary mitigations
RR-CM-01	Bispecific chain mispairing / product-related impurities (homodimers, half-antibody, aggregates) inadequately controlled at scale	3	4	High (12)	Medium (6)	VPCMC	Engineered heterodimerization with orthogonal purification; dual potency release (anti-TL1A neutralization + IL-22R agonism); characterization of charge variants, glycosylation, and aggregates; specifications set per ICH Q6B
RR-CM-02	Scale-up comparability failure (Phase 2 → commercial CHO process) affecting quality or bridging	4	4	High (16)	Medium (6)	VPCMC	Pre-defined comparability protocol (ICH Q5E); QbD design space; representative engineering/PPQ lots; stability bridging
RR-CM-03	Aggregation/stability limits of the high-concentration SC formulation	3	3	Medium (9)	Low (4)	VPCMC	Polysorbate-stabilized buffer optimization; forced-degradation and real-time/accelerated stability per ICH Q1A(R2)/Q5C; shelf-life 24 months at 2–8 °C
RR-CM-04	Device integration and human-factors risk (prefilled syringe/autoinjector)	3	3	Medium (9)	Low (4)	CPL	Design-control per device regulation; formative and summative human-factors studies; delivery-accuracy and use-error mitigation
RR-CM-05	Single-CDMO / single-source raw-material dependency threatening supply	3	4	High (12)	Medium (6)	VPCMC	Second-source qualification roadmap; safety-stock strategy; robust quality/technical agreements and CDMO oversight

4.4 Nonclinical Risks

Table 4-4. Nonclinical risk register

ID	Risk	L	I	Inherent	Residual	Owner	Primary mitigations
RR-NC-01	Absence of a pharmacologically relevant rodent species limiting translational and safety extrapolation	4	3	High (12)	Medium (6)	HNC	ICH S6(R1)-compliant strategy: cynomolgus monkey as relevant species (repeat-dose SC), knock-in/surrogate pharmacology in disease models, tissue cross-reactivity, and safety pharmacology
RR-NC-02	Carcinogenicity/proliferation uncertainty specific to chronic IL-22R agonism	3	4	High (12)	Medium (6)	HNC	Weight-of-evidence carcinogenicity assessment per ICH S6(R1) (dedicated rodent carcinogenicity studies not warranted for a mAb); chronic-toxicology GI proliferation endpoints; clinical malignancy surveillance
RR-NC-03	Reproductive/developmental toxicology feasibility and timeline (enhanced pre/postnatal assessment in NHP)	3	3	Medium (9)	Low (4)	HNC	ePPND (enhanced pre- and postnatal development) study strategy agreed with health authorities; placental-transfer considerations (IgG1 transfer rising across the second and third trimesters) reflected in contraception guidance and labeling; genotoxicity not expected for a mAb per ICH S6(R1)

4.5 Operational and Business Risks

Table 4-5. Operational and business risk register

ID	Risk	L	I	Inherent	Residual	Owner	Primary mitigations
RR-OP-01	Virtual operating model: heavy CRO/CDMO reliance with attendant oversight and quality-continuity risk	4	4	High (16)	Medium (9)	PMO	Vendor governance framework; risk-based monitoring and QA audit program; defined KPIs; retained in-house medical, regulatory, and technical accountability
RR-OP-02	Confirmatory-phase recruitment shortfall in a competitive UC/TL1A trial landscape	4	4	High (16)	Medium (9)	HCO	Broad multi-regional site footprint; competitive-enrollment feasibility analytics; patient-identification and retention programs; stratification by prior biologic exposure to protect power
RR-OP-03	Comparator/competitive landscape eroding trial feasibility and commercial differentiation	4	3	High (12)	Medium (6)	CBO	Differentiation on the complementary anti-inflammatory + mucosal-healing mechanism and dose-ordered efficacy (remission High 37.3% vs Placebo 0.7%); ongoing competitive-intelligence monitoring; lifecycle/positioning strategy
RR-OP-04	Data integrity / GCP compliance across distributed vendors and sites	3	4	High (12)	Medium (6)	HQA	Centralized/statistical data surveillance; risk-based site monitoring; audit and inspection-readiness program aligned to ICH E6(R3)
RR-OP-05	Program funding / continuity for a capital-intensive confirmatory program	3	5	High (15)	Medium (8)	CEO/CBO	Staged investment gated to milestones; partnering/financing strategy; scenario-based portfolio planning

5. Priority Risk Narratives

The following risks carry the highest inherent scores or the greatest residual uncertainty and receive dedicated governance attention.

RR-CL-01 Immunogenicity. As an SC-administered bispecific IgG1, TILA-278 carries an inherent immunogenicity risk that could reduce exposure, attenuate efficacy, or, rarely, alter safety. Immunogenicity is assessed with a validated, tiered assay (screening, confirmatory, titre, and neutralizing-antibody tiers), with pre-specified analyses of impact on PK, efficacy, and safety. In Study TILA278-201, treatment-emergent ADA were observed in 7.9% of TILA-278-treated subjects, predominantly low-titre and transient, with neutralizing antibodies in 2.1%; no meaningful attenuation of Week 12 remission was seen across ADA strata and no ADA-associated hypersensitivity was identified. Residual risk is managed through ADA-covariate population-PK modelling to confirm the confirmatory dose and dosing interval, and through continued immunogenicity monitoring in the extension.

RR-CL-02 IL-22R agonism and epithelial proliferation. The IL-22R-agonist arm is intended to drive epithelial regeneration and mucosal-barrier repair; the same biology carries a theoretical risk of promoting aberrant epithelial proliferation, of particular concern in a chronically inflamed colon predisposed to colitis-associated neoplasia. This low-likelihood, high-impact risk is addressed nonclinically through chronic cynomolgus toxicology with detailed gastrointestinal histopathology and proliferation endpoints, and clinically through a long-term pharmacovigilance plan incorporating malignancy surveillance and exposure caps anchored to the nonclinical no-observed-adverse-effect level. Because the underlying biological hazard cannot be eliminated pre-clinically, it is retained at Medium residual risk and is a standing item at safety governance.

RR-CL-04 Durability of response. The available efficacy data derive from a 12-week induction study and demonstrate dose-ordered, clinically and statistically robust induction of remission (High 37.3%, Low 16.2%, Placebo 0.7%; LS-mean modified-Mayo change vs placebo: High −2.36 [95% CI −2.49, −2.23], Low −1.77 [95% CI −1.90, −1.64]; both p < 0.0001). Durability beyond induction is not yet established. The confirmatory program is designed to include a maintenance phase (treat-through and/or randomized-withdrawal) with a long-term extension to characterize durability and loss-of-response, retiring this High inherent risk to Medium residual.

RR-RA-01 Novel mechanism precedent. No IL-22R agonist has been approved, and the bispecific TL1A-antagonist/IL-22R-agonist mechanism is first-in-class. Regulatory acceptance of the benefit-risk and long-term safety framework is therefore not assured. Mitigation centers on early and iterative health-authority engagement (scientific advice, End-of-Phase-2), a rigorous ICH S6(R1)-based nonclinical justification, and a pre-agreed long-term safety and risk-management plan proportionate to the novel biology.

RR-CM-01/RR-CM-02 Bispecific manufacturability and scale-up. Bispecific antibodies are susceptible to chain mispairing and elevated product-related impurities (homodimers, half-antibody, aggregates), and scale-up from clinical to commercial CHO manufacturing must preserve both binding activities and the impurity profile. Control is achieved through an engineered heterodimerization platform with orthogonal purification, dual potency release covering anti-TL1A neutralization and IL-22R agonism, and a QbD-based process with a pre-defined comparability protocol per ICH Q5E supported by representative engineering and process-performance-qualification lots. These are priority CMC risks through the transition to commercial scale.

RR-OP-01/RR-OP-02 Virtual operating model and recruitment. As a virtual sponsor, Virtual Biopharma Inc. depends on CROs and CDMOs for execution, creating oversight, quality-continuity, and enrollment-control exposures that are amplified in a competitive UC and TL1A trial landscape. Mitigation rests on a formal vendor-governance framework with risk-based monitoring, defined KPIs, and a QA audit and inspection-readiness program, together with retained in-house medical, regulatory, and technical accountability. Recruitment risk is managed through a broad multi-regional site footprint, feasibility analytics, and stratified enrollment (baseline modified-Mayo severity and prior biologic exposure) to protect statistical power.

RR-OP-05 Funding and continuity. The confirmatory program is capital-intensive and, as a program-threatening risk, is managed through milestone-gated staged investment, an active partnering/financing strategy, and scenario-based portfolio planning under Board and executive oversight.

6. Risk Monitoring, Review, and Escalation

The register is reviewed on a defined cadence and upon trigger events. Standard review is monthly at the Program Team and quarterly at the Development Governance Committee. Any risk crossing into the High band, any new Critical-impact risk, and any material change in residual score triggers immediate escalation to governance with a corrective-action plan.

Each risk carries defined monitoring indicators and escalation triggers, for example: an increase in confirmed neutralizing-ADA incidence above the pre-specified threshold (RR-CL-01); an adjudicated malignancy or proliferative histopathology signal (RR-CL-02); a comparability-protocol deviation (RR-CM-02); enrollment tracking below 80% of the site-activation-adjusted plan for two consecutive months (RR-OP-02); or a critical vendor audit finding (RR-OP-01/RR-OP-04). Owners are accountable for maintaining current mitigation status, evidence of effectiveness, and residual-score justification. The PMO reconciles the register against the integrated development plan and the Risk Management Plan and ensures traceability to the supporting assessments in Modules 2, 3, and 5 of this dossier.

7. Summary

The TILA-278 program presents a manageable risk profile appropriate to a first-in-class bispecific biologic advancing from a positive Phase 2b induction readout toward a confirmatory program. The dominant residual risks are the establishment of maintenance-phase durability, regulatory acceptance of a novel IL-22R-agonist mechanism, bispecific manufacturability at commercial scale, and the oversight demands of a virtual operating model. Each is subject to a defined mitigation with an accountable owner, an escalation trigger, and governance oversight. With these mitigations in effect, all identified risks are held at Low or Medium residual banding, and no risk is currently assessed as program-terminating. The register will be maintained as a living instrument through the confirmatory program and marketing-application preparation.